Table 1.
Baseline patient characteristics in sex/BMI categories for 10 593 patients
| Normal weight | Overweight | Obesity | ||||
|---|---|---|---|---|---|---|
| Parameter | Women | Men | Women | Men | Women | Men |
| N = 3092 | N = 773 | N = 2561 | N = 1257 | N = 2191 | N = 718 | |
| 80.0% | 20.0% | 67.1% | 32.9% | 75.3% | 24.7% | |
| Age, years | 55.6 (13.9) | 57.7 (13.5) | 59.4 (12.3) | 58.8 (11.3) | 58.2 (11.6) | 57.4 (10.7) |
| BMI, kg/m2 | 22.3 (1.7) | 23.0 (1.6) | 27.3 (1.4) | 27.2 (1.4) | 34.8 (4.4) | 33.3 (3.2) |
| Smoking habits | ||||||
| Never smoked [n, (%)] | 1409 (45.6) | 199 (25.7) | 1265 (49.4) | 258 (20.5) | 1053 (48.0) | 151 (21.0) |
| Ever smoked [n (%)] | 1530 (49.5) | 550 (71.2) | 1142 (44.6) | 959 (76.3) | 1017 (46.4) | 540 (75.2) |
| Smoking habits unknown [n (%)] | 153 (4.9) | 24 (3.1) | 154 (6.0) | 40 (3.2) | 122 (5.6) | 27 (3.8) |
| Disease activity | ||||||
| ESR | 25.7 (19.2) | 30.3 (24.3) | 28.1 (20.4) | 29.7 (23.2) | 30.7 (21.2) | 28.5 (22.0) |
| CRP | 9.5 (8.9) | 16.0 (15.4) | 10.0 (9.1) | 14.7 (13.9) | 11.8 (10.1) | 13.6 (12.4) |
| Swollen joint count | 4.9 (4.2) | 5.1 (4.4) | 5.0 (4.3) | 5.1 (4.5) | 5.1 (4.4) | 5.0 (4.5) |
| Tender joint count | 7.0 (5.9) | 6.8 (6.0) | 7.8 (6.6) | 7.2 (6.2) | 8.6 (7.1) | 7.7 (6.6) |
| Patient global health assessment | 5.4 (2.2) | 5.4 (2.1) | 5.7 (2.1) | 5.7 (2.1) | 6.1 (2.0) | 5.8 (2.0) |
| DAS28-ESR | 4.7 (1.3) | 4.7 (1.4) | 4.9 (1.3) | 4.8 (1.4) | 5.1 (1.2) | 4.8 (1.3) |
| DAS28-ESR <3.2 [n (%)] | 415 (13.4) | 111 (14.4) | 253 (9.9) | 160 (12.7) | 159 (7.2) | 84 (11.7) |
| 3.2 ≤ DAS28-ESR < 5.1 [n (%)] | 1549 (50.1) | 358 (46.4) | 1200 (46.9) | 555 (44.1) | 938 (42.8) | 340 (47.3) |
| 5.1 ≤ DAS28-ESR [n (%)] | 1128 (36.5) | 303 (39.2) | 1108 (43.3) | 542 (43.1) | 1095 (50.0) | 295 (41.0) |
| Disease history, function | ||||||
| Disease duration, years | 10.0 (9.1) | 7.7 (8.2) | 9.8 (9.0) | 7.2 (7.3) | 8.7 (8.4) | 6.3 (6.6) |
| Joint erosions [n (%)] | 1628 (54.5) | 374 (50.1) | 1228 (50.3) | 549 (46.1) | 801 (38.8) | 284 (41.2) |
| Number of previous csDMARDs | 2.2 (1.1) | 1.8 (1.0) | 2.1 (1.1) | 1.8 (1.0) | 2.0 (1.1) | 1.8 (0.9) |
| Number of previous bDMARDs | 0.4 (0.9) | 0.3 (0.7) | 0.4 (0.8) | 0.3 (0.8) | 0.4 (0.8) | 0.4 (0.8) |
| % of full physical function | 70.3 (22.0) | 74.7 (20.9) | 64.6 (22.5) | 72.7 (21.6) | 58.3 (22.4) | 67.6 (22.7) |
| Comorbidities | ||||||
| No comorbidities [n (%)] | 981 (31.7) | 249 (32.2) | 504 (19.7) | 270 (21.5) | 261 (11.9) | 100 (13.9) |
| One comorbidity [n (%)] | 795 (25.7) | 192 (24.8) | 595 (23.2) | 327 (26.0) | 457 (20.8) | 177 (24.7) |
| Two comorbidities [n (%)] | 549 (17.8) | 128 (16.6) | 524 (20.5) | 237 (18.9) | 455 (20.8) | 134 (18.7) |
| ≥3 comorbidities [n (%)] | 767 (24.8) | 204 (26.4) | 938 (36.6) | 423 (33.7) | 1019 (46.5) | 307 (42.8) |
| Sum of comorbidities | 1.7 (2.0) | 1.8 (2.1) | 2.3 (2.2) | 2.2 (2.2) | 2.8 (2.4) | 2.6 (2.4) |
| Autoantibody status | ||||||
| RF or ACPA positive [n (%)] | 2512 (81.2) | 606 (78.4) | 1949 (76.1) | 965 (76.8) | 1544 (70.4) | 522 (72.7) |
| Glucocorticoid therapy | ||||||
| Any glucocorticoids in last 6 months [n (%)] | 1706 (55.2) | 452 (58.5) | 1449 (56.6) | 725 (57.7) | 1245 (56.8) | 398 (55.5) |
| Glucocorticoid dose in last 6 monthsa | 6.8 (3.4) | 7.5 (3.9) | 6.7 (3.2) | 7.7 (3.9) | 6.9 (3.3) | 8.2 (4.5) |
| DMARD therapy | ||||||
| csDMARDs [n (%)] | 883 (28.6) | 240 (31.0) | 822 (32.1) | 416 (33.1) | 792 (36.1) | 240 (33.4) |
| TNFi [n (%)] | 1451 (46.9) | 379 (49.0) | 1162 (45.4) | 583 (46.4) | 957 (43.7) | 316 (44.0) |
| Abatacept [n (%)] | 165 (5.3) | 32 (4.1) | 117 (4.6) | 64 (5.1) | 109 (5.0) | 44 (6.1) |
| Rituximab [n (%)] | 210 (6.8) | 47 (6.1) | 175 (6.8) | 72 (5.7) | 100 (4.6) | 44 (6.1) |
| Tocilizumab [n (%)] | 383 (12.4) | 75 (9.7) | 285 (11.1) | 122 (9.7) | 234 (10.7) | 74 (10.3) |
Means (s.d.) are reported if not otherwise specified. Non-integer numbers for categorical variables resulting from multiple imputation are rounded. aConsidering only patients who received glucocorticoids. DAS28-ESR: DAS with 28 joints using ESR as an inflammation marker; csDMARD: conventional synthetic DMARD; bDMARD: biologic DMARD.